Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a peanut allergen extract developed by the University of North Carolina, Chapel Hill, for the treatment of peanut allergy via sublingual immunotherapy (SLIT). The extract, manufactured by Greer Laboratories, contains peanut protein at a concentration of 5000 μg/mL. It is administered as a liquid under the tongue to induce immune desensitization and potentially long-term clinical tolerance. Research at UNC has focused on children (ages 1-4 and older), demonstrating that maintenance doses of 2-4 mg of peanut protein can safely increase reaction thresholds and, in some cases, lead to sustained tolerance after treatment cessation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on peanut allergen extract (UNC Chapel Hill).